Navigation Links
Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People
Date:3/11/2011

FRIDAY, March 11 (HealthDay News) -- Taking aspirin to protect against colorectal cancer may be effective, but mostly in people at increased risk for the disease due to elevated levels of an inflammatory biomarker in their blood, according to a new study.

Previous research has found that people who take aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) have a reduced risk of colorectal cancer. Other studies have noted that inflammation contributes to the development of conditions such as cardiovascular disease and several types of cancer.

In this new study, researchers at Massachusetts General Hospital and the Dana-Farber Cancer Institute found that elevated baseline levels of an inflammatory marker called "soluble tumor necrosis factor receptor-2 (sTNFR-2)" were associated with increased risk of colorectal cancer and also predicted who might benefit from taking aspirin or other NSAIDs, such as ibuprofen or naproxen.

The researchers analyzed data from 280 participants in the Nurses' Health Study who were cancer-free when they provided a blood sample in 1989 and 1990, but developed colorectal cancer over the next 14 years. These patients were compared to 555 age-matched participants who did not develop colorectal cancer.

The researchers analyzed baseline levels of three inflammatory markers -- sTNFR-2, c-reactive protein (CRP), and interleukin-6 (IL-6). There was no association between levels of CRP or IL-6 and risk of developing colorectal cancer. But people with the highest levels of sTNFR-2 were 60 percent more likely to develop colorectal cancer than those with the lowest levels of the factor.

The researchers also found that the reduced risk of colorectal cancer associated with regular use of aspirin or other NSAIDs was primarily seen among people with high baseline levels of sTNFR-2.

The study appears in the March issue of the journal Gastroenterology.

"These findings suggest that a blood biomarker may be helpful in deciding whether individuals should take aspirin or NSAIDs to reduce their cancer risk," lead author Dr. Andrew Chan, of the gastrointestinal unit at Massachusetts General Hospital, said in a hospital news release.

"They also indicate that chronic inflammatory pathways are quite complex, and further studies are needed to understand which facets of the inflammatory response are most associated with the development of colorectal cancer," he added.

More information

The U.S. National Cancer Institute has more about colorectal cancer prevention.

-- Robert Preidt

SOURCE: Massachusetts General Hospital, Dana-Farber Cancer Institute, news release, March 9, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Aspirins ability to protect against colorectal cancer may depend on inflammatory pathways
2. Small bowel blood flow in healthy subjects receiving low-dose aspirin
3. Low-Dose Aspirin Boosts Accuracy of Colon Cancer Test
4. Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent
5. Daily Aspirin Linked to Steep Drop in Cancer Risk
6. Bleeding Risk With Plavix-Aspirin Regimen May Be Serious
7. Aspirin May Help Patients Beat Prostate Cancer
8. Aspirin, Statins May Reduce Problems After Heart Surgery
9. IV Aspirin Drip Appears to Be Safe, Effective for Migraine
10. Low-Dose Aspirin May Reduce Colon Cancer Risk
11. Can aspirin prolong a healthy life?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People
(Date:8/17/2017)... ... August 17, 2017 , ... Dr. Charles ... Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, eBook, 9781498497633) focuses on the treatment ... of memories and achieve forgiveness, through a progressive journey toward healing. This book ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Momkus McCluskey ... newest Partner. Ms. Parks is a member of the firm’s Commercial Litigation and Employment ... and provides a wealth of knowledge in matters of employment litigation, commercial litigation and ...
(Date:8/17/2017)... ... , ... A recent report indicates that circa 79 percent of 483 warning ... data integrity. The FDA outlines their expectations for quality critical instrumentation in the GMP ... the Beckman Coulter Life Sciences Virtual Trade Show Virtual Event, this webinar ...
(Date:8/16/2017)... ... August 16, 2017 , ... Blue Health Intelligence (BHI) ... President, Chief Medical Officer. Dr. Spiro brings over 30 years of clinical, healthcare IT, ... for BHI’s cutting-edge analytics solutions. , “I am thrilled to welcome Dr. Spiro ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, ... that it was acquired by Advantage Solutions. The Data Council’s IX-ONE platform ... include the industry’s leading suppliers, brokers, distributors and retailers. The Data Council will ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... -- Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam Elhofy , ... on Cell-Ess® Universal Titer Boost at the 9 th ... August 21-25.  The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals ... ... Cell-Ess is ...
(Date:8/15/2017)... -- AccuGenomics, Inc., a diagnostic company based in ... company has provided an AccuKit to the HIV Cure ... Hill and to Qura Therapeutics for evaluation in HIV ... reservoir and viral expression in human CD4+ T cells ... is a joint initiative between the University of North ...
(Date:8/10/2017)... -- Physical Rehabilitation Network (PRN), acquired the long-standing outpatient rehabilitation clinic, ... . The reputable clinic will continue to be co-owned and ... staff of four clinicians. Lipkin received his doctorate in physical ... years of experience with a strong background in manual therapy. ... 10th PRN clinic in and around the Denver ...
Breaking Medicine Technology: